Effects of bifidobacterium triple viable enteric coated capsule combined with pentoxifylline on renal function and prognosis in elderly patients with early diabetic nephropathy
10.3760/cma.j.cn115455-20230406-00329
- VernacularTitle:双歧杆菌三联活菌肠溶胶囊联合己酮可可碱对老年早期糖尿病肾病患者肾功能和预后的影响
- Author:
Xiaodi WANG
1
;
Yutao GAO
;
Xudong LU
Author Information
1. 河北省第八人民医院内分泌消化科，石家庄 050000
- Keywords:
Diabetic nephropathies;
Aged;
Pentoxifylline;
Prognosis;
Bifidobacterium triple viable enteric capsules;
Kidney function;
Intestinal flora
- From:
Chinese Journal of Postgraduates of Medicine
2023;46(11):1020-1026
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of bifidobacterium triple viable enteric coated capsule combined with pentoxifylline on renal function and prognosis in elderly patients with early diabetic nephropathy.Methods:The clinical data of 110 elderly patients with type 2 diabetes mellitus (T2DM) complicated with early diabetes nephropathy in Hebei Eighth People′s Hospital from May 2020 to May 2022 were retrospectively analyzed. All patients were given routine dietary control, exercise therapy and insulin therapy. On this basis, 55 patients were treated with pentoxifylline (control group), and 55 patients were treated with bifidobacterium triple viable enteric coated capsule combined with pentoxifylline (study group). The efficacy 3 months after treatment was evaluated, and the adverse reactions were record. Before treatment and after 1 and 3 months of treatment, the blood glucose indexes (including fasting blood glucose, FBG; 2 h postprandial blood glucose, 2 h PBG; insulin sensitivity index, Matsuda index), renal function indexes (including urea nitrogen; creatinine; urinary microalbumin excretion rate, UAER), intestinal flora amount (including bifidobacterium, lactobacillus, enterococcus and escherichia coli) and inflammatory response stress indexes (including interleukin-6, IL-6; transforming growth factor β 1, TGF-β 1; malondialdehyde; reactive oxygen species) were measured. Results:Three months after treatment, the total effective rate in study group was significantly higher than that in control group: 94.55% (52/55) vs. 81.82% (45/55), and there was statistical difference ( χ2 = 4.27, P<0.05). There was no statistical difference in the incidence of adverse reactions between study group and control group: 3.64% (2/55) vs. 10.91% (6/55), χ2 = 1.21, P>0.05. There were no statistical differences in all indexes before treatment between study group and control group ( P>0.05). The FBG and 2 h PBG after 1 and 3 months of treatment in study group were significantly lower than those in control group; while the Matsuda index was significantly higher than that in control group, with statistical differences ( P<0.01). The creatinine, urea nitrogen and UAER after 1 and 3 months of treatment in study group were significantly lower than those in control group, with statistical differences ( P<0.01). The amounts of bifidobacterium and lactobacillus after 1 and 3 months of treatment in study group were significantly higher than those in control group, while the amounts of enterococcus and escherichia coli were significantly lower than those in control group, with statistical differences ( P<0.01 or <0.05). The IL-6, TGF-β 1, malondialdehyde and reactive oxygen species after 1 and 3 months of treatment in study group were significantly lower than those in control group, with statistical differences ( P<0.01). Conclusions:Bifidobacterium triple viable enteric coated capsule combined with pentoxifylline is effective and safe in elderly patients with early diabetes nephropathy in the. It can effectively control blood sugar level and improve renal function, which may be related to regulating intestinal flora and inhibiting inflammatory reaction stress state.
